Recent Developments in Receptor-Selective Retinoids
The DOI matches its Crossref record.
Abstract
Natural (all trans-retinoic acid, RA) and synthetic retinoids exhibit potent anti-proliferative, normalization of differentiation and anti-inflammatory activities which appear to account for their therapeutic effects in acne, psoriasis, photoaging, precancerous lesions and established cancers. Although RA has shown considerable promise in dermatologic indications, certain side effects have restricted its use as a choice of agent for chronic administration. Systematic synthesis of receptor-selective retinoids has resulted in two topical drugs, Tazorac/Zorac (tazarotene) and Differin (adapalene). Tazorac is indicated for psoriasis and acne and Differin gel for the treatment of acne. These drugs bind to the retinoic acid receptor (RAR) family members. Various RAR subtype-specific and function-selective retinoids have been synthesized. These retinoids, which are in various stages of pre-clinical development for the treatment of cancers, psoriasis and as an antidote to Accutane-mediated mucocutaneous toxicity, will also be discussed in this review. Discovery of another retinoid receptor, retinoid X receptor (RXR), revealed that RXR-specific retinoids already existed in retinoid chemical libraries. Structure activity relationship studies based upon binding and transactivation assays led to the synthesis of RXR-specific ligands with high affinities for RXR subtypes. These compounds were found to be effective in the treatment of hyperglycemia in animal models of type II diabetes. The discovery of novel retinoids along with an increased understanding of the biological functions and mechanisms of action of retinoid receptors are likely to result in improved treatments for existing responsive indications and identification of new retinoid therapeutic targets. Keywords: Adpalene, Tazarotene, Retinoic acid receptor, Retinoid X receptor, Retinoic acid, Squamous cell carcinoma, Pan agonists, Induced genes, Repressed genes, Receptor selective retinoids, Differin (Adapalene CD 271), Human polymorphonuclear (PMN) leukocytes, RAR alpha specific Retinoids, Promyelocytic leukemia (PML) gene, RAR antagonists inverse agonists, CREB binding protein
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Gene expression regulation by retinoic acid
Balmer, J. E., & Blomhoff, R. (2002) · Journal of Lipid Research · doi:10.1194/jlr.r100015-jlr200 · Cited by 1,039
“Two more specialized reviews, on receptor-specific ligands (7) and on discoveries made through receptor knockouts (8), expand on topics that turn up frequently in the Gene Table, but are treated only generically.”
BackgroundPhotoaging: mechanisms and repair
Rabe, J. H., Mamelak, A. J., McElgunn, P. J. S., Morison, W. L., & Sauder, D. N. (2006) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2005.05.010 · Cited by 610
Retinoids and their receptors in cancer development and chemoprevention
Sun, S.-Y., & Lotan, R. (2002) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(01)00144-5 · Cited by 324
Current Concepts of the Pathogenesis of Acne: Implications for Drug Treatment
Gollnick, H. (2003) · Drugs · doi:10.2165/00003495-200363150-00005 · Cited by 230
DiSepio, D., Ghosn, C., Eckert, R. L., Deucher, A., Robinson, N., Duvic, M., Chandraratna, R. A. S., & Nagpal, S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.25.14811 · Cited by 171
Self-citation
Metadata
- Authors
- Nagpal, S., & Chandraratna, R.
- Venue
- Current Pharmaceutical Design
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2000-06-01
- Volume
- 6
- Issue
- 9
- Pages
- 919-931
- ISSN
- 1381-6128 (ISSN-L)
- OpenAlex
- W2007600985
- Cited by
- 113
- References
- 0
- FWCI
- 2.93
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Recent Developments in Receptor-Selective Retinoids. https://app.cochat.ai/papers/10.2174/1381612003400146
- The paper
- Nagpal, S., & Chandraratna, R. (2000). Recent Developments in Receptor-Selective Retinoids. Current Pharmaceutical Design. https://doi.org/10.2174/1381612003400146
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.